Best Initial Medication for Elderly Patient with Short-Term Memory Loss

Cholinesterase Inhibitor Options

The American Academy of Family Physicians recommends Donepezil (Aricept) as the first-line medication for a patient with short-term memory loss due to Alzheimer's disease, starting at 5 mg once daily, which can be increased to 10 mg once daily after 4-6 weeks if needed 1, 2
Donepezil has advantages including once-daily dosing, no hepatotoxicity, and mild side effects, with side effects including nausea, vomiting, and diarrhea, which can be reduced by taking with food 1, 2
Rivastigmine (Exelon) has an initial dosage of 1.5 mg twice daily, with gradual titration up to 6 mg twice daily, and requires twice-daily dosing, which may affect adherence in patients with memory issues 1
Galantamine (Reminyl) has an initial dosage of 4 mg twice daily, taken with meals, and is contraindicated in patients with hepatic or renal impairment 1, 3
Tacrine (Cognex) is now considered a second-line agent due to its side effect profile, including elevation of liver enzyme levels in 40% of treated patients, and must be administered four times daily due to its short half-life 1, 4

Once-daily dosing of Donepezil improves medication adherence in elderly patients with memory problems, and it has no hepatotoxicity, unlike Tacrine 1, 2
Donepezil can be taken with food to minimize gastrointestinal side effects, and its side effects include nausea, vomiting, and diarrhea 1

The recommended initial dosage of Donepezil is 5 mg once daily for at least 4-6 weeks before considering dose increase, and the dose can be increased to 10 mg daily if well-tolerated and greater efficacy is needed 1, 2
Taking Donepezil with the evening meal may help if insomnia or nightmares occur 5

Beneficial response to Donepezil may take 6-12 months to assess properly, and response should be determined by the physician's global assessment of the patient, the primary caregiver's report, and evidence of behavioral or functional changes 1
Brief mental status tests are relatively insensitive measures of cholinesterase inhibitor effects 1

Cholinesterase inhibitors provide modest benefits (5-15% over placebo), and consideration should be given to discontinuation if side effects develop and do not resolve, adherence is poor, deterioration continues at pre-treatment rate after 6-12 months, or the patient progresses to severe or end-stage dementia 1, 2, 6
Patients who don't respond to one cholinesterase inhibitor may respond to another, and these inhibitors should be avoided in patients with mild cognitive impairment (MCI) without dementia, as evidence doesn't support use in this population 1, 6

Vitamin E (2000 IU daily) may be considered as an adjunct therapy to slow functional decline, and non-pharmacological interventions should be implemented alongside medication, including establishing predictable routines, simplifying tasks, creating a safe environment, and using calendars, clocks, and labels for orientation 1, 4